Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TTI-0102, a Cysteamine Precursor for Mild to Moderate TBI: Dosing and Feasibility Study

NCT04262895 is registered in ClinicalTrials.gov with VA Office of Research and Development as lead sponsor.

NCT NCT04262895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04262895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TTI-0102, a Cysteamine Precursor for Mild to Moderate TBI: Dosing and Feasibility Study
Lead sponsor
VA Office of Research and Development
Phase
Phase 1/2
Overall status
Withdrawn
Start date
October 1, 2021
Completion date
October 15, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mild to moderate tbi, posttraumatic stress disorder